Clarus Therapeutics Announces FDA Award of 3-Year Market Exclusivity for Jatenzo®

JATENZO® is a first-in-class proprietary softgel oral formulation of…


Clarus Therapeutics Refutes Patent Infringement Complaint

NORTHBROOK, Ill – April 3, 2019 – Clarus Therapeutics, Inc. today announced…


Clarus Re-submits JATENZO NDA Following Positive Results of inTUne Trial

87% of Hypogonadal Men Treated with JATENZO in Confirmatory Phase 3 Study…


Clarus Therapeutics Initiates Phase 3 Clinical Trial of Oral Testosterone Replacement Therapy

NORTHBROOK, Ill. – May 17, 2016 – Clarus Therapeutics, Inc., a men's health…


Clarus Therapeutics Reports FDA Advisory Committees Vote on REXTORO(TM) for Low Testosterone in Men

NORTHBROOK, Ill., Sept. 18, 2014 -- Clarus Therapeutics, Inc. announced today…